Primary Progressive Aphasia - Pipeline Insight, 2019
This report can be delivered to the clients within 24 Hours
"Primary Progressive Aphasia - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary Progressive Aphasia pipeline landscape is provided which includes the disease overview and Primary Progressive Aphasia treatment guidelines. The assessment part of the report embraces, in depth Primary Progressive Aphasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Progressive Aphasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Primary Progressive Aphasia Understanding
Primary Progressive Aphasia (PPA) is a neurological syndrome in which language capabilities become slowly and progressively impaired. Unlike other forms of aphasia that result from stroke or brain injury, PPA is caused by neurodegenerative diseases, such as Alzheimer’s disease or Frontotemporal Lobar Degeneration. PPA results from deterioration of brain tissue important for speech and language. Although the first symptoms are problems with speech and language, other problems associated with the underlying disease, such as memory loss, often occur later. PPA commonly begins as a subtle disorder of language, progressing to a nearly total inability to speak, in its most severe stage. The type or pattern of the language deficit may differ from patient to patient. The initial language disturbance may be fluent aphasia (i.e., the person may have normal or even increased rate of word production) or non-fluent aphasia (speech becomes effortful and the person produces fewer words). A less common variety begins with impaired word-finding and progressive deterioration of naming and comprehension, with relatively preserved articulation.
Primary Progressive Aphasia Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Primary Progressive Aphasia targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Primary Progressive Aphasia pipeline report covers 6+ companies. Some of the key players include Axon Neuroscience (AADvac1) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Primary Progressive Aphasia Analytical Perspective by DelveInsight
Scope of the report
"Primary Progressive Aphasia - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary Progressive Aphasia pipeline landscape is provided which includes the disease overview and Primary Progressive Aphasia treatment guidelines. The assessment part of the report embraces, in depth Primary Progressive Aphasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Progressive Aphasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Primary Progressive Aphasia Understanding
Primary Progressive Aphasia (PPA) is a neurological syndrome in which language capabilities become slowly and progressively impaired. Unlike other forms of aphasia that result from stroke or brain injury, PPA is caused by neurodegenerative diseases, such as Alzheimer’s disease or Frontotemporal Lobar Degeneration. PPA results from deterioration of brain tissue important for speech and language. Although the first symptoms are problems with speech and language, other problems associated with the underlying disease, such as memory loss, often occur later. PPA commonly begins as a subtle disorder of language, progressing to a nearly total inability to speak, in its most severe stage. The type or pattern of the language deficit may differ from patient to patient. The initial language disturbance may be fluent aphasia (i.e., the person may have normal or even increased rate of word production) or non-fluent aphasia (speech becomes effortful and the person produces fewer words). A less common variety begins with impaired word-finding and progressive deterioration of naming and comprehension, with relatively preserved articulation.
Primary Progressive Aphasia Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Primary Progressive Aphasia targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Primary Progressive Aphasia pipeline report covers 6+ companies. Some of the key players include Axon Neuroscience (AADvac1) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Primary Progressive Aphasia Analytical Perspective by DelveInsight
- In-depth Primary Progressive Aphasia Commercial Assessment of products
- Primary Progressive Aphasia Clinical Assessment of products
Scope of the report
- The Primary Progressive Aphasia report provides an overview of therapeutic pipeline activity for Primary Progressive Aphasia across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Primary Progressive Aphasia therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Primary Progressive Aphasia Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Primary Progressive Aphasia
- Establish a comprehensive understanding of the current pipeline scenario across Primary Progressive Aphasia to formulate effective R&D strategies
- Assess challenges and opportunities that influence Primary Progressive Aphasia R&D
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Get in detail information of each product with updated information on each project along with key milestones
- Devise Primary Progressive Aphasia in licensing and out licensing strategies by identifying prospective partners with progressing projects for Primary Progressive Aphasia to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION
2. PRIMARY PROGRESSIVE APHASIA
2.1. Primary Progressive Aphasia Disease Overview
2.2. Primary Progressive Aphasia History
2.3. Primary Progressive Aphasia Symptoms
2.4. Primary Progressive Aphasia Causes
2.5. Primary Progressive Aphasia Pathophysiology
2.6. Primary Progressive Aphasia Diagnosis
2.6.1. Diagnostic Guidelines
3. PRIMARY PROGRESSIVE APHASIA CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. PRIMARY PROGRESSIVE APHASIA - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Primary Progressive Aphasia companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Primary Progressive Aphasia Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Primary Progressive Aphasia Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. PRIMARY PROGRESSIVE APHASIA PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. PRIMARY PROGRESSIVE APHASIA -PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. AADvac1- Axon Neuroscience
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. PRIMARY PROGRESSIVE APHASIA KEY COMPANIES
8.1. Axon Neuroscience
8.2. GE Healthcare
8.3. Eisai Co Ltd
8.4. Avid Radiopharmaceuticals
8.5. Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
8.6. Alector Inc.
9. PRIMARY PROGRESSIVE APHASIA KEY PRODUCTS
9.1. AADvac 1
9.2. Fluorine-18-THK 5351
9.3. Donepezil
9.4. Flortaucipir F 18
9.5. galantamine hydrobromide
9.6. AL001
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. PRIMARY PROGRESSIVE APHASIA - UNMET NEEDS
12. PRIMARY PROGRESSIVE APHASIA - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
2. PRIMARY PROGRESSIVE APHASIA
2.1. Primary Progressive Aphasia Disease Overview
2.2. Primary Progressive Aphasia History
2.3. Primary Progressive Aphasia Symptoms
2.4. Primary Progressive Aphasia Causes
2.5. Primary Progressive Aphasia Pathophysiology
2.6. Primary Progressive Aphasia Diagnosis
2.6.1. Diagnostic Guidelines
3. PRIMARY PROGRESSIVE APHASIA CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. PRIMARY PROGRESSIVE APHASIA - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Primary Progressive Aphasia companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Primary Progressive Aphasia Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Primary Progressive Aphasia Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. PRIMARY PROGRESSIVE APHASIA PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. PRIMARY PROGRESSIVE APHASIA -PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. AADvac1- Axon Neuroscience
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. PRIMARY PROGRESSIVE APHASIA KEY COMPANIES
8.1. Axon Neuroscience
8.2. GE Healthcare
8.3. Eisai Co Ltd
8.4. Avid Radiopharmaceuticals
8.5. Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
8.6. Alector Inc.
9. PRIMARY PROGRESSIVE APHASIA KEY PRODUCTS
9.1. AADvac 1
9.2. Fluorine-18-THK 5351
9.3. Donepezil
9.4. Flortaucipir F 18
9.5. galantamine hydrobromide
9.6. AL001
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. PRIMARY PROGRESSIVE APHASIA - UNMET NEEDS
12. PRIMARY PROGRESSIVE APHASIA - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
LIST OF TABLES
Table 1. Primary Progressive Aphasia Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Primary Progressive Aphasia Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Table 1. Primary Progressive Aphasia Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Primary Progressive Aphasia Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
LIST OF FIGURES
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Primary Progressive Aphasia companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Primary Progressive Aphasia Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
Axon Neuroscience
GE Healthcare
Eisai Co Ltd
Avid Radiopharmaceuticals
Biogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
IntraBio Inc
Genzyme, a Sanofi Company|Sanofi
FORUM Pharmaceuticals Inc
CTD Holdings, Inc.
Alexion Pharmaceuticals
Alector Inc.
Aldagen
Actelion
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Primary Progressive Aphasia companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Primary Progressive Aphasia Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
Axon Neuroscience
GE Healthcare
Eisai Co Ltd
Avid Radiopharmaceuticals
Biogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
IntraBio Inc
Genzyme, a Sanofi Company|Sanofi
FORUM Pharmaceuticals Inc
CTD Holdings, Inc.
Alexion Pharmaceuticals
Alector Inc.
Aldagen
Actelion
